Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria
- 1 July 2010
- journal article
- research article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 100 (3) , 229-233
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiencyMolecular Genetics and Metabolism, 2009
- Optimizing the use of sapropterin (BH4) in the management of phenylketonuriaMolecular Genetics and Metabolism, 2009
- Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted dietJournal of Neurology, Neurosurgery & Psychiatry, 2009
- What we know that could influence future treatment of phenylketonuriaJournal of Inherited Metabolic Disease, 2008
- The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R‐tetrahydrobiopterin): a phase II, multicentre, open‐label, screening studyJournal of Inherited Metabolic Disease, 2007
- Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled studyThe Lancet, 2007
- Executive functioning in children and adolescents with phenylketonuriaClinical Genetics, 2007
- National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16–18, 2000Pediatrics, 2001
- Maternal phenylketonuria: A metabolic teratogenTeratology, 1996
- PKU in adolescents: rationale and psychosocial factors in diet continuationActa Paediatrica, 1994